health

Kane Biotech Files New Patent on Bone Tissue Regeneration Invention

September 2, 2011

WINNIPEG, Manitoba (August 30, 2011) - Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms, is pleased to announce the invention and patenting of a new bone tissue regenerating fusion peptide based on the Company’s competence stimulating peptide (CSP) oral care technology.

This new patent covers the invention of a unique combination product using the Company’s CSP technology to help grow bone cells by enhancing bone cell binding and bone tissue regeneration.

The invention can be used for: (i) osteogenic cell binding for repairing the dental bone defects such as those caused by bone loss resulting from moderate to severe periodontitis, (ii) filling tooth extraction sites or sinus elevation grafting, (iii) treatment of fractures, (iv) using as a filler in bone, (v) prevention of decrease in the bone substance related to osteoporosis, and (vi) prevention of fractures associated with osteoporosis and rheumatoid arthritis.

The global market for bone tissue regeneration is over $32 billion a year. This includes dental bone grafts, osteoporosis, osteoarthritis and rheumatoid arthritis. The dental bone graft global market alone is estimated at $266 million per year.

“This exciting new invention gives us the opportunity to discuss our technology platforms in a new global market as we continue to focus our near term resources and attention on DispersinB®”, stated Mr. Gord Froehlich, President and Chief Executive Officer of Kane Biotech.

“In addition to antimicrobial activity against dental cavity and periodontal diseases associated bacteria, we are excited to learn our CSP-based technology has potential to be used in combination with bone tissue regenerating products for the treatment of diseases and defects related to bone loss and bone regeneration”, added Mr. Froehlich.

Share This Story

Back

“This exciting new invention gives us the opportunity to discuss our technology platforms in a new global market as we continue to focus our near term resources and attention on DispersinB®”. -Mr. Gord Froehlich, President and Chief Executive Officer of Kane Biotech.